Key result
Lorlatinib causes hypercholesterolemia in ~73% of patients without increasing cardiovascular events versus crizotinib.
Why the study?
Prolonged lorlatinib treatment in ALK-positive NSCLC extends cumulative exposure to hypercholesterolemia and hypertriglyceridemia, raising considerations for atherosclerotic prevention alongside an unresolved question regarding venous thromboembolism risk.
Does lorlatinib-associated dyslipidemia increase atherosclerotic cardiovascular risk or venous thromboembolism in patients with ALK-positive non-small cell lung cancer, and how should it be managed?
Does lorlatinib-associated dyslipidemia increase atherosclerotic cardiovascular risk or venous thromboembolism in patients with ALK-positive non-small cell lung cancer, and how should it be managed?
Answers are grounded in this paper and cite their sources.
Long-term lorlatinib therapy in ALK-positive NSCLC causes frequent, persistent dyslipidemia (>70% of patients) requiring prompt management with non-CYP3A4-metabolized statins like rosuvastatin or pravastatin for atherosclerotic prevention, though its impact on venous thromboembolism remains unproven.
Lorlatinib, a brain-penetrant third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, has markedly improved outcomes in ALK-positive non-small cell lung cancer (NSCLC). In the CROWN trial, median progression-free survival had not been reached with first-line lorlatinib after 7 years of follow-up, compared with 9.1 months for crizotinib, with 7-year progression-free survival of 55% versus 3%. Median treatment duration was 62.6 months versus 9.6 months. This duration extends cumulative exposure to lorlatinib's characteristic metabolic toxicity: hypercholesterolemia and hypertriglyceridemia. At 7 years, these occurred in 73% and 71% of patients receiving lorlatinib, with grade 3 or 4 events in 22% and 26%. Onset is rapid, at a median of about 2 weeks. At 5 years, any-grade elevations had persisted for a median of 36 to 38 months; 71% of events were managed with lipid-lowering agents. ALK-positive NSCLC carries a high risk of venous thromboembolism across observational cohorts and a meta-analysis, more so for venous than arterial events. Laboratory evidence suggests the EML4-ALK fusion raises tissue factor through the pERK1/2-AP-1 pathway. At 7 years, aggregate cardiovascular adverse events were similar between treatment groups, and venous events were not more frequent with lorlatinib; small event counts and differing treatment exposure limit comparison of individual events. Statin choice is limited because lorlatinib is a moderate cytochrome P450 3A inducer; rosuvastatin and pravastatin are preferred. We review lorlatinib-associated dyslipidemia and its management and separate two claims: prompt, guideline-concordant lipid management is supported by established atherosclerotic prevention principles, whereas any effect on venous thromboembolism remains untested.
No takes yet. Share an insight, caveat, or question.
Gopu et al. (2026) conducted a review in ALK-positive non-small cell lung cancer (NSCLC) and lorlatinib-associated dyslipidemia. Lorlatinib vs. Crizotinib was evaluated on Hypercholesterolemia and hypertriglyceridemia at 7 years (CROWN trial data reviewed). Lorlatinib caused hypercholesterolemia and hypertriglyceridemia at 7 years in ALK-positive NSCLC, though aggregate cardiovascular and venous events were not increased versus crizotinib.
Synapse has enriched 10 related papers. Consider them for comparative context: